Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
LA JOLLA, Calif., May 08, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2017 financial results after the close of U.S. financial markets on May 15, 2017. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 14001186. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 14001186.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
